adenosine/stroke

The present invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. Publications in this area include WO 98/16539 (Novo Nordisk A/S) which describes adenosine derivatives for the treatment of

BACKGROUND OF THE INVENTION Extracellular adenosine acts as a local modulator at four subtypes of adenosine receptors, namely, A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3, which are involved in numerous physiological and pathophysiological processes. Fredholm et al., Pharmacol. Rev. 2001; 53:527-52.

FIELD OF THE INVENTION This invention pertains to A.sub.3 and A.sub.1 adenosine receptor agonists, pharmaceutical compositions comprising such agonists, and a method of use thereof, for example, in treating various medical disorders. BACKGROUND OF THE INVENTION Extracellular adenosine acts as a

BACKGROUND OF THE INVENTION Extracellular adenosine acts as a local modulator at four subtypes of adenosine receptors, namely, A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3, which are involved in numerous physiological and pathophysiological processes. Fredholm et al., Pharmacol. Rev. 2001; 53:527-52.

The present invention relates to 2-aminothiophene derivatives, pharmaceutical compositions containing them, and to methods of treating conditions mediated by the A.sub.1 adenosine receptor including pain, in particular, chronic pain such as neuropathic pain, cardiac disease or disorder such as

The present invention relates to 2-aminothiophene derivatives, pharmaceutical compositions containing them, and to methods of treating conditions mediated by the A.sub.1 adenosine receptor including pain, in particular, chronic pain such as neuropathic pain, cardiac disease or disorder such as

FIELD OF THE INVENTION The present invention relates to novel triazolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of treating conditions and diseases mediated by the adenosine A.sub.2A receptor activity, by employing such compounds. BACKGROUND OF THE

TECHNICAL FIELD The instant invention relates generally to methods of manipulating angiogenesis and more specifically it relates to the use of compounds which are selective adenosine A.sub.1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis in animal subjects. These

BACKGROUND OF THE INVENTION This invention pertains to N-piperazineacetamide derivatives of 4,5-diphenyl-oxazoles, thiazoles and imidazoles having drug and bio-affecting properties and to their preparation and use. In particular the compounds of this invention are novel adenosine reuptake inhibitors

BACKGROUND OF THE INVENTION Extracellular adenosine acts as a local modulator at four subtypes of adenosine receptors, namely, A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3, which are involved in numerous physiological and pathophysiological processes. Fredholm et al., Pharmacol. Rev. 2001; 53:527-52.

FIELD OF THE INVENTION The present invention relates to novel triazolopyrimidine derivatives, pharmaceutical compositions containing them, and methods of treating conditions and diseases mediated by the adenosine A.sub.2A receptor activity, by employing such compounds. BACKGROUND OF THE

BACKGROUND OF THE INVENTION There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the

BACKGROUND OF THE INVENTION There are four subtypes of receptors for adenosine, designated A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3. The A.sub.3 adenosine receptor is found primarily in the central nervous system, brain, testes, and the immune system, where it appears to be involved in the

BACKGROUND This invention relates to substituted 1,2,4-triazolo[1,5-c]pyrimidine adenosine A.sub.2a receptor antagonists, the use of said compounds in the treatment of central nervous system diseases, in particular Parkinson's disease, and to pharmaceutical compositions containing said

TECHNICAL FIELD The present invention relates to a novel pyrazine derivative and a salt thereof, which are useful as medicaments. BACKGROUND ART Adenosine is a ubiquitous biochemical messenger. Adenosine binds to and activates seven-transmembrane spanning G-protein coupled receptors, eliciting a